pre-IPO PHARMA

COMPANY OVERVIEW

Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to the development of innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval


LOCATION

  • Seattle, WA, USA

  • THERAPEUTIC AREAS

  • Neurological Disorders
  • Pain

  • WEBSITE

    https://www.receptorlife.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Nov 1, 2022

    Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)


    Jun 29, 2022

    Receptor Life Sciences Announces First Patient Dosed with RLS103 (Inhaled Dry Powder CBD) in Phase 1b/2a Clinical Study in Acute Anxiety within Social Anxiety Disorder


    Apr 7, 2022

    Receptor Life Sciences Secures $9.7 Million Financing to Advance RLS103 (Inhaled Dry Powder CBD) into Clinical Trials


    Mar 30, 2022

    Receptor Life Sciences Announces FDA Acceptance of IND Application for RLS103 (Inhaled Dry Powder CBD) and Initiation of IND-Opening Clinical Safety and Efficacy Study


    Aug 17, 2021

    Receptor Life Sciences Announces Publication of Proof-of-Principle Clinical Pharmacokinetics Study of RLS103 (Inhaled Dry Powder CBD)


    For More Press Releases


    Google Analytics Alternative